Biotech Values

[DewDiligence]

IDIX 2009-2010 News Flow

[Updated for 3Q09 CC.]


HCV

11/2/09-11/3/09: Two presentations at AASLD pertaining to IDX184 (#msg-43061222). On Nov 2, IDIX presents the full dataset from the 3-day monotherapy study; on Nov 3, IDIX presents the results of the DDI study.

4Q09: Start phase-2 trial of IDX184. The trial will test three or four doses of IDX184 + SoC for 14 days. (Patients will then continue on SoC alone for another 14 days.)

4Q09: Start phase-1 trial of IDX375. (A CTA was submitted during 3Q09.)

4Q09: Submit IND/CTA for IDX316. Start phase-1 trial in 1Q010.

Late 2009/early 2010: Ink IDX184 partnership.

Mid 2010: Report top-line results of phase-2 IDX184 trial.

2010(?): Submit IND/CTA for lead compound from NS5A program.


HIV

Early 2010: GSK* starts phase-2 IDX899 trial.

*As operator of the GSK-PFE JV for HIV drug development.